VERVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.16 USD | -0.96% |
|
-7.23% | -55.81% |
| 04-03 | Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating | MT |
| 04-02 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
Chart calendar Verve Therapeutics, Inc.
3.wDE9cc6JuHti7jPi0R6aIEzTjD4x1_v4Tu_fWibCE1s.jX1QJJrL7U03qgG153PAQwmrvFlosrq3fLbpd2uzfQyJeX9JiqTMNijdVA~51928be446b2a1bbdbdcac7696238b7e
Upcoming events on Verve Therapeutics, Inc.
Past events on Verve Therapeutics, Inc.
| 27/02/2024 12:30 | Q4 2023 Earnings Release |
| 08/02/2024 16:30 | Guggenheim Healthcare Talks Biotechnology Conference |
| 09/01/2024 00:30 | JPMorgan Healthcare Conference |
| 16/11/2023 11:30 | Jefferies London Healthcare Conference |
| 14/11/2023 21:45 | Stifel Healthcare Conference |
| 12/11/2023 23:30 | Business Update Call |
| 12/11/2023 23:30 | Investor Meeting |
| 12/11/2023 20:30 | American Heart Association Scientific Meeting |
| 07/11/2023 11:30 | Q3 2023 Earnings Release |
| 28/09/2023 15:55 | Cantor Global Healthcare Conference |
| 27/08/2023 09:25 | European Society of Cardiology Congress |
| 14/08/2023 | Stifel Biotech Executive Summit |
| 10/08/2023 16:30 | Canaccord Genuity Growth Conference |
| 10/08/2023 11:30 | Q2 2023 Earnings Release |
| 15/06/2023 15:00 | Annual General Meeting |
| 08/06/2023 20:00 | Jefferies Global Healthcare Conference |
| 30/05/2023 21:10 | Stifel Tailoring Genes Genetic Medicines Day |
| 16/05/2023 14:30 | RBC Global Healthcare Conference |
| 15/05/2023 11:30 | Q1 2023 Earnings Release |
| 03/04/2023 15:45 | Guggenheim Genomic Medicines and Rare Disease Day |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 1,94 1,02 89.82% | 11,8 7,54 56.03% | 13,0 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -85,5 -83,6 -2.34% | -163 -154 -6.05% | -218 -226 3.57% | -264 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -87,1 -80,9 -7.58% | -166 -161 -2.85% | -223 -224 0.47% | -234 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -120 -115 -4.56% | -157 -158 0.51% | -200 -206 2.8% | -226 |
|
Net income Million USD | Released Forecast Spread | -45,7 | -120 -115 -4.99% | -157 -158 0.47% | -200 -206 2.77% | -226 |
|
EPS USD | Released Forecast Spread | 0,00 | -4,48 -3,23 -38.7% | -2,91 -3,02 3.61% | -3,12 -3,29 5.17% | -2,93 |
| Announcement Date | 28/05/21 | 14/03/22 | 02/03/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,93 0,83 11.48% | 1,01 0,44 128.51% | 1,40 0,51 173% | 2,09 0,67 211.15% | 3,12 1,08 187.51% | 5,14 1,17 340.7% | 2,25 | 2,64 | 2,26 | 5,98 | 3,00 |
|
EBITDA Million USD | Released Forecast Spread | -32,1 -29,0 -10.58% | -43,1 -30,9 -39.58% | -46,8 -40,8 -14.81% | -50,9 -62,0 17.97% | -62,0 | -65,0 | -69,0 | -73,0 | ||||||
|
EBIT Million USD | Released Forecast Spread | -32,5 -26,4 -23.21% | -31,9 -33,9 5.88% | -42,2 -34,1 -23.73% | -43,9 -41,0 -7.06% | -47,7 -45,2 -5.58% | -58,3 -48,7 -19.54% | -58,6 -57,9 -1.13% | -52,3 -60,2 13.1% | -53,9 -57,3 5.83% | -57,7 | -59,1 | -61,4 | -60,4 | -64,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -31,3 -26,4 -18.92% | -30,2 -33,7 10.56% | -40,9 -33,9 -20.76% | -45,2 -42,3 -6.79% | -41,0 -44,2 7.07% | -52,0 -47,6 -9.1% | -53,8 -57,5 6.35% | -45,7 -58,1 21.31% | -48,3 -54,1 10.75% | -55,1 | -56,6 | -59,1 | -57,6 | -64,0 |
|
Net income Million USD | Released Forecast Spread | -31,3 -25,8 -21.36% | -30,2 -33,7 10.56% | -40,9 -33,9 -20.76% | -45,2 -42,3 -6.79% | -41,1 -44,6 7.84% | -52,0 -47,6 -9.1% | -54,0 -57,5 6.04% | -45,8 -58,1 21.2% | -48,4 -54,1 10.7% | -55,1 | -56,6 | -59,1 | -57,6 | -64,0 |
|
EPS USD | Released Forecast Spread | -0,65 -0,53 -22.64% | -0,62 -0,65 5.09% | -0,84 -0,64 -30.28% | -0,79 -0,74 -7.21% | -0,67 -0,76 11.84% | -0,84 -0,78 -7.92% | -0,87 -0,92 5.02% | -0,72 -0,92 21.45% | -0,69 -0,82 15.46% | -0,71 | -0,73 | -0,76 | -0,73 | -0,87 |
| Announcement Date | 14/03/22 | 10/05/22 | 09/08/22 | 07/11/22 | 02/03/23 | 15/05/23 | 10/08/23 | 07/11/23 | 27/02/24 | - | - | - | - | - |
| Today 21:05 | QIAGEN N.V.: Q1 2024 Earnings Release |
| 29/04/2024 | CRISPR THERAPEUTICS AG: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | DYNE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | PROTAGONIST THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | EDITAS MEDICINE, INC.: Q1 2024 Earnings Release (Projected) |
| 30/04/2024 | AZENTA, INC.: Q2 2024 Earnings Release (Projected) |
| 01/05/2024 11:30 | UNITED THERAPEUTICS CORPORATION: Q1 2024 Earnings Release |
| 01/05/2024 11:30 | BIO-TECHNE CORPORATION: Q3 2024 Earnings Release |
| 01/05/2024 12:00 | ALKERMES PLC: Q1 2024 Earnings Release |
| 01/05/2024 | VIR BIOTECHNOLOGY, INC.: Q1 2024 Earnings Release |
Past sector events for Verve Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- VERV Stock
- Calendar Verve Therapeutics, Inc.
